29.5.2024
Cardiac diseases and cancers are leading causes of death [1]. Many cancer patients have preexistent cardiac impairment or have risk factors of developing it. On the other hand, survival after being diagnosed with cancer is increasing, so relatively more patients may develop long-term side effects. Cardiac diseases and cancers are…
Articles
1.5.2024
HELSINKI, Finland - May 1, 2024 An application for MVision AI Segmentation (Contour+) has been submitted and accepted by the Therapeutic Goods Administration (TGA) under the “Image Segmentation Application Software” for image analysis algorithms to be used in radiation therapy treatment planning workflows. Contour+ accelerates the contouring process, provides guidance…
Press Releases
29.4.2024
Helsinki, Uusimaa - April 29, 2024 – MVision AI, a pioneering company in developing innovative AI solutions in the radiation oncology & imaging space, proudly announces the appointment of Dharanipathy Rangaraj as its new Chief Executive Officer (CEO). In his new capacity as CEO of MVision AI, Dharani will spearhead…
19.2.2024
Finland, Helsinki, February 19, 2024 The contract for installing Contour+ Guideline Based AI Segmentation tool has been won through the public tender process and implies a three-year agreement for 5,000 scans per year. This order comes in quick succession following MVision AI's successful award of the tender from the Republic…
2.2.2024
World cancer day, celebrated on the 4th of February, was established more than 20 years ago. It represents an initiative of the Union for International Cancer Control (UICC) , the oldest and largest global membership organization dedicated to taking action on cancer. UICC has over 1150 member organizations in 172…
News
22.1.2024
HELSINKI, Finland - January 22, 2024 MVision AI, a premier software service provider of GBS™ (Guideline-Based Segmentation) solution for same-day radiotherapy treatment planning, proudly announces a new distribution partnership with Medron Medical Systems, a leading health equipment provider in Canada. This collaboration follows the receipt of Medical Device License (MDL)…
19.1.2024
Results of MVision AI’s solutions scientific evaluation were presented at the previous ASTRO annual meeting. One of the posters included data from paired MRI and synthetic CT scans (MRCAT) of male pelvis and showed the accuracy and consistency of Contour+ models. The abstract was published in Volume 117 Issue 2…
9.1.2023
S Warren, N Richmond MVision AI software has been under evaluation at NCCC (Newcastle upon Tyne Hospitals NHS Foundation Trust) since 28 February 2022* in order to: 1. compare AI contour quality and consistency with manual contouring; 2. estimate potential improvements in efficiency; 3. identify opportunities to improve clinical workflow.…
17.6.2022
Background Worldwide, more than 1 400 000 men were diagnosed with prostate cancer in 2020, and it is estimated that one third will need radiotherapy during their treatment. (more…)
19.1.2022
Helsinki - 19th of January, 2022 - MVision AI, the leading provider of the guideline-based solution, collaborates with EduCase, the global leader in web-based education designed to support contouring skill instructions for radiation oncologists. EduCase is a computer-based training tool developed by RadOnc eLearning Center, LLC., to assist the development…
News, Press Releases
7.1.2022
According to the NHS, breast cancer is the most common type of cancer in the UK. Roughly 1 in 8 women are diagnosed with breast cancer during their lifetime. However, there is a good chance of recovery if the cancer is detected early. (NHS) The World Health Organization estimates that…
29.12.2021
2021 is an innovative and foundational year for MVision AI. We are proud of what we have accomplished so far and super excited about what is in store for us in the future. One feeling that stands out as we look back at 2021 is gratitude. We thank everyone who…
Subscribe to get information, latest news and other interesting offers about MVision AI